Investigating a new drug that targets cancer cells by inhibiting the proteasome
Characterization of A Novel Proteasome Inhibitor
This study is looking at a new treatment called Rapaprotin that might help kill cancer cells without harming healthy ones, and it's aimed at improving options for people with multiple myeloma and other tough-to-treat cancers.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11058426 on NIH RePORTER |
What this research studies
This research focuses on a novel proteasome inhibitor called Rapaprotin, which has shown promise in selectively inducing cell death in cancer cells while sparing normal cells. The approach involves screening a library of compounds to identify those that effectively inhibit proteasome activity, which is crucial for cancer cell survival. By understanding how Rapaprotin works, the research aims to improve treatment options for patients with multiple myeloma and potentially other cancers, especially those resistant to existing therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with multiple myeloma or other cancers that may benefit from proteasome inhibition.
Not a fit: Patients with non-cancerous conditions or those who do not have multiple myeloma or related cancers may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and less toxic treatments for patients with multiple myeloma and other cancers.
How similar studies have performed: Previous research has shown success with other proteasome inhibitors, indicating a strong potential for this novel approach.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Liu, Jun O. — Johns Hopkins University
- Study coordinator: Liu, Jun O.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.